Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) Earns Daily News Sentiment Score of 0.09

Media coverage about Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE:BIO) has been trending somewhat positive recently, according to Accern. The research group identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Bio-Rad Laboratories, Inc. Class A Common Stock earned a news sentiment score of 0.09 on Accern’s scale. Accern also gave news articles about the medical research company an impact score of 46.7775482113528 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

BIO has been the subject of a number of analyst reports. ValuEngine raised shares of Bio-Rad Laboratories, Inc. Class A Common Stock from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. Jefferies Financial Group raised their price target on shares of Bio-Rad Laboratories, Inc. Class A Common Stock to $325.00 and gave the stock a “buy” rating in a report on Wednesday, February 28th. Citigroup raised their price target on shares of Bio-Rad Laboratories, Inc. Class A Common Stock to $325.00 and gave the stock a “buy” rating in a report on Wednesday, February 28th. CL King cut shares of Bio-Rad Laboratories, Inc. Class A Common Stock from a “buy” rating to a “neutral” rating in a report on Friday, February 16th. Finally, Wells Fargo & Co raised their target price on shares of Bio-Rad Laboratories, Inc. Class A Common Stock from $280.00 to $290.00 and gave the stock an “outperform” rating in a report on Tuesday, March 20th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $297.20.

BIO stock traded up $2.64 during midday trading on Thursday, hitting $303.70. 83,500 shares of the stock traded hands, compared to its average volume of 159,482. The firm has a market cap of $8.97 billion, a PE ratio of 73.83, a P/E/G ratio of 3.27 and a beta of 1.00. The company has a debt-to-equity ratio of 0.10, a quick ratio of 2.99 and a current ratio of 4.33. Bio-Rad Laboratories, Inc. Class A Common Stock has a 1-year low of $208.95 and a 1-year high of $304.36.

Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE:BIO) last released its quarterly earnings results on Tuesday, May 8th. The medical research company reported $1.17 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.07 by $0.10. Bio-Rad Laboratories, Inc. Class A Common Stock had a net margin of 34.32% and a return on equity of 3.84%. The company had revenue of $551.52 million for the quarter, compared to analyst estimates of $527.20 million. During the same quarter last year, the business earned $0.68 earnings per share. The firm’s revenue was up 10.3% on a year-over-year basis. research analysts predict that Bio-Rad Laboratories, Inc. Class A Common Stock will post 6.13 earnings per share for the current fiscal year.

Bio-Rad Laboratories, Inc. Class A Common Stock Company Profile

Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.

Insider Buying and Selling by Quarter for Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Inc. Class A Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. Class A Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply